The Cooper Companies, Inc (COO)
Key Takeaways:
Company Overview
The Cooper Companies, Inc. is a global medical device company organized around two franchises: CooperVision, which sells contact lenses and specialty eye-care products, and CooperSurgical, which provides fertility, women’s health, genetic testing, cryostorage and related medical devices and services. CooperVision’s portfolio spans daily, two-week and monthly silicone-hydrogel lenses, including the Biofinity, MyDay and clariti families, plus MiSight, the only FDA-approved lens to slow myopia progression in children at treatment initiation. CooperSurgical serves OB/GYN offices, hospitals and fertility clinics with a broad set of devices, IVF-related products, donor gametes, genomic services, contraception and storage services. The business is global, complex and heavily regulated, with meaningful exposure to pricing pressure, reimbursement risk, foreign exchange, supply-chain fragility, litigation, and evolving FDA/EU/UK rules. Growth is supported by secular myopia management demand, contact-lens modality shifts, fertility market expansion and healthcare consolidation, but execution risk is high given debt, integration complexity, regulatory burden and competitive intensity.
Business Segments
Economic Moat Analysis
Cooper has a real but not impregnable competitive advantage. Its moat comes mainly from regulatory barriers, product differentiation in specialty contact lenses, and a broad global distribution footprint. MiSight is a particularly important asset because it is clinically distinctive and carries notable regulatory validation in multiple markets. However, the company does not appear to have a wide moat because competition is strong, switching costs are moderate at best, pricing is pressured, and much of the business depends on continued innovation, execution and regulatory compliance. The result is a narrow moat with pockets of defensibility rather than a durable, enterprise-wide fortress.
Biofinity, MyDay, clariti and MiSight are established brands, but brand strength is meaningful rather than dominant versus the largest peers.
Medical-device approvals, clinical evidence requirements and quality-system obligations create real barriers that protect incumbents, though they are not insurmountable.
Switching costs exist through practitioner preference, fitting routines and clinic workflows, but they are not high enough to create a deep lock-in effect.
MiSight and the broad toric/multifocal portfolio provide differentiated clinical value, especially in myopia management and specialty contact lenses.
Global manufacturing and distribution scale help service large customers and support breadth of SKU coverage, but peers also operate at significant scale.
Patents, trade secrets and technical know-how matter, but contact lens and medical-device IP is contestable and vulnerable to litigation or circumvention.
Key Strengths
- Diversified Franchises: The company spans two distinct medical-device end markets, reducing dependence on any single product line or procedure type.
- MiSight Differentiator: MiSight’s unique FDA, China and Japan approvals for slowing childhood myopia give CooperVision a meaningful clinical and commercial edge.
- Global Reach: Sales in more than 130 countries and operations across multiple regions provide scale and geographic diversification.
- Recurring Demand: Contact lenses, fertility consumables, genomic services and storage offerings create repeat-purchase characteristics rather than one-time sales.
- Brand Portfolio: Biofinity, MyDay and clariti provide coverage across premium, mid-tier and value segments, improving channel penetration.
- Regulatory Barriers: Extensive approvals, quality systems and clinical evidence requirements raise barriers to entry for weaker competitors.
- Customer Diversification: No single customer represented 10% or more of revenue, reducing concentration risk at the top line.
- Operating Cash Flow: Strong operating cash generation provides flexibility for debt service, buybacks and reinvestment.
Identified Weaknesses
- Leverage: Debt remains substantial, limiting financial flexibility and raising vulnerability to rate and refinancing risk.
- Margin Pressure: Gross margin and CooperSurgical operating income were pressured by write-offs, severance and amortization charges.
- Regulatory Complexity: The business depends on continuous compliance across FDA, EU MDR/IVDR, UK MHRA, CLIA and other regimes.
- Integration Risk: Growth has relied on acquisitions, which increases execution risk, systems complexity and goodwill/intangible impairment exposure.
- Customer Power: Consolidation among optical chains, hospitals and fertility clinics can compress pricing and reduce bargaining leverage.
- Foreign Exchange: A large international revenue base creates translation and transaction volatility, especially in pound, euro and yen exposure.
- Control Risk: A prior material weakness in IT general controls indicates the risk of process and ERP execution problems.
- Reimbursement Exposure: CooperSurgical’s demand is sensitive to third-party payor coverage, healthcare reform and Medicaid-related pricing pressure.
Growth Opportunities
- Myopia Growth: Rising childhood myopia rates and broader acceptance of proactive management could expand MiSight adoption and related specialty demand.
- Modal Shift: Continued migration from monthly and two-week lenses toward daily silicone-hydrogel products supports premium mix and volume growth.
- Fertility Expansion: Rising infertility, older maternal age and broader access to IVF services may sustain long-term demand growth.
- Consolidated Buying: Provider and clinic consolidation may favor large vendors that can standardize supply, service and education across networks.
- Genomics Upside: Genetic testing and genomic services may grow if clinical utility and reimbursement improve, despite regulatory noise.
- Emerging Markets: Low contact-lens penetration in many markets leaves room for long-term share gains if execution and regulation permit.
- Operational Improvement: ERP stabilization, manufacturing efficiency and supply-chain optimization could expand margins if management executes well.
- Portfolio Acquisitions: Selective tuck-in deals could deepen channel access or broaden fertility and women’s-health offerings, though integration risk remains high.
Risk Factors
- Intense Competition: Johnson & Johnson, Alcon, Bausch + Lomb, Vitrolife and others have scale advantages, deeper budgets or strong niche positions.
- Regulatory Shock: Changes in FDA, EU MDR/IVDR, MHRA, CLIA or HCT/P interpretations could delay launches, increase costs or force product changes.
- Supply Disruption: Reliance on sole or primary suppliers for certain materials creates inventory and continuity risk.
- Pricing Pressure: Competitive discounting and payer reimbursement pressure could compress margins, especially in CooperSurgical.
- Litigation Risk: Product liability, intellectual property disputes, recall events and service-related claims could be costly and reputationally damaging.
- Trade Friction: Tariffs, export controls, sanctions and geopolitical fragmentation could raise costs and disrupt cross-border operations.
- Cyber Risk: Connected-device and health-data exposure make ransomware, data theft and operational disruption credible threats.
- Alternative Technologies: LASIK, new pharmaceuticals, telemedicine-led vision correction and evolving reproductive technologies could erode demand over time.
Valuation Metrics
COO trades at P/E 19.29 and Forward P/E 12.01, implying the market expects a material earnings acceleration. For value, this is moderately priced; for growth, it suggests upside if forward estimates hold.
Earnings growth premium looks contained: PEG 1.63 (above 1) indicates you’re not getting “cheap-for-growth” pricing; valuation is fair-to-slightly rich relative to expected growth.
Price-to-sales is P/S 2.54, which is reasonable for a profitable medical/healthcare company; it supports value case if margins/earnings remain resilient.
Balance-sheet price tags: P/B 1.29. This is not an asset-bargain multiple; it’s consistent with a business where intangibles/brand and earning power matter more than book value.
Cash-flow valuation: P/FCF 15.85 and EV/EBITDA 15.85. These are mid-range multiples—neither screamingly cheap nor expensive.
Net balance sheet intensity appears manageable: Enterprise Value 13.14B vs Market Cap 10.75B suggests net debt/adjustments are meaningful, but not extreme given the multiples.
Earnings & Profitability
Profitability is strong and relatively high-quality: ROA 10.95%, ROE 15.85%, and ROIC 10.95%. This indicates returns are not only accounting-driven.
Margins support both value durability and growth: Gross Margin 43.89%, Operating Margin 40.73%, and Profit Margin 26.14% (very robust for many industrial/medical device businesses).
Earnings scale is strong: EPS (ttm) 7.39 with EPS this Y 10.25% (interpreting as current-year EPS growth trend), and EPS next Y 7.35%. The presence of forward EPS acceleration is favorable for a growth investor.
Reinvestment/quality check: EPS/Sales Surprise 0.56% suggests only modest recent beats; it reduces confidence in near-term “beat-and-raise” momentum, but profitability remains solid.
Top-line growth backdrop (TTM): Sales Y/Y TTM 4.73% while EPS Y/Y TTM 355.30% is unusually high—this often occurs from a low base, restructuring, or one-time normalization. A value investor should verify whether the EPS surge is repeatable.
Growth Analysis
Forward-looking earnings expectations are supportive: Forward P/E 12.01 alongside EPS outlook suggests improving earnings trajectory.
Analyst-style growth metric: EPS next 5Y 7.39% indicates mid-single to low double-digit compound growth—more “steady growth” than hyper-growth.
Historical EPS growth is extremely strong: EPS past 3/5Y 355.30% (very large). Because that number is extreme, treat it as a signal to investigate cyclicality/one-offs, but it does support a possible multi-year re-rating if fundamentals persist.
Revenue momentum is positive but not explosive: Sales past 3/5Y 43.89% and Sales Y/Y TTM 4.73%. This fits a model of margin-driven earnings growth rather than purely revenue-driven growth.
Quarterly trends appear mixed: EPS Q/Q -1.15% while Sales Q/Q 9.30%. Growth may currently be sales-led while earnings timing is softer.
Financial Health
Liquidity is adequate: Quick Ratio 0.73 and Current Ratio 1.22. Not “fortress,” but serviceable for an established med-tech business.
Leverage looks controlled: Debt/Eq 0.31 and LT Debt/Eq 0.23, suggesting balance sheet risk is not excessive.
Quality of capital returns is high (ROA/ROE/ROIC all ~11–16%), which typically correlates with durable cash generation.
Working capital/financing risk appears moderate given current liquidity ratios; focus on execution rather than balance-sheet stress.
Ownership Structure
Insider ownership is low: Insider Own 0.62%. This implies limited insider signaling via ownership concentration.
Institutional ownership is high: Inst Own 2.93% in the dataset’s units (likely formatted strangely). Even with possible formatting issues, the presence of institutional involvement typically supports liquidity and underwriting stability.
Insider transactions are listed as Insider Trans -2.93% (dataset shows negative), which may indicate selling/less buying recently—moderately cautionary for near-term sentiment.
Market Performance
Trend vs key moving averages: price is above SMA20 3.29 and SMA50 10.01 in the dataset’s magnitude terms, and close to/near the longer-term trend at SMA200 89.83 (note: the SMA values in the dataset appear inconsistent in scale; interpret cautiously). Net takeaway: the stock has seen volatility and recent drawdown/mean reversion signals.
52-week range: 52W High 189.26, 52W Low 112.65. With current Price 151.01, COO is in the upper-middle of the range, not at distressed levels.
Recent performance is mixed/soft: Perf Week 2.57%, Month 3.32%, but Quarter -16.24%, Half Y -21.07%, and YTD -21.43%. This suggests a valuation reset or macro/sector pressure rather than a clean trend up.
Volatility is moderate: Volatility 0.62 and ATR (14) 3.03. Beta 0.82 indicates less market sensitivity than the broader market (defensive tilt).
Momentum & Volatility
RSI (14) is 35.18, which is in the lower range (leaning oversold-ish). This can support a value entry if fundamentals are intact, but it can also reflect ongoing earnings/expectation concerns.
Short positioning is notable: Short Float 3.29% and Short Ratio 0.82 (dataset suggests buy-side balance is not extreme). Short interest 19.26%* appears inconsistent with the other fields; treat short metrics as “elevated but not panic.”
Relative volume Rel Volume 1.61 indicates heavier-than-usual trading—often occurs around catalysts or re-rating phases.
Price momentum looks weaker on longer horizons (quarter/half/YTD negative), despite short-term stabilization (week/month positive).
Investment Recommendations
value Investor:
Target a pullback zone around $140–$145. Rationale: current price ($151.01) is not deeply discounted; RSI ~35 suggests some weakness already priced in, so waiting for confirmation (or a modest discount) improves margin of safety.
growth Investor:
Consider entries around $135–$145 if you can underwrite ~mid-single to low double-digit EPS growth (~7.39% next 5Y) plus the benefit implied by forward P/E (12.01). If price holds above ~$145 with improving estimates, you can scale closer to $148–$152.
Investment Summary
COO shows strong profitability (ROA/ROE/ROIC ~11–16%) and high margins (gross ~44%, profit ~26%). Valuation is fair to slightly growth-friendly (P/E 19.3; forward 12.0; PEG 1.63). Growth looks steady (EPS ~7.39% next 5Y) with mixed quarterly signals. Financial health is moderate leverage (Debt/Eq 0.31; current ratio 1.22). Momentum is soft YTD, RSI ~35 suggests a better risk/reward on pullbacks. Value: wait for ~$140–$145. Growth: scale ~$135–$145.